Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $57

Benzinga Newsdesk www.benzinga.com Positive 85.1%

Neg 0% Neu 0% Pos 85.1%

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $56 to $57.